RT Journal Article
SR Electronic
T1 Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.15.21267867
DO 10.1101/2021.12.15.21267867
A1 Sebbag, Clara
A1 Rousset-Jablonski, Christine
A1 Coussy, Florence
A1 Ray-Coquard, Isabelle
A1 Garin, Clémentine
A1 Evrevin, Clémence
A1 Toussaint, Aullène
A1 Cessot, Marion
A1 Labrosse, Julie
A1 Laot, Lucie
A1 Darrigues, Lauren
A1 Bobrie, Angélique
A1 Jacot, William
A1 Sénéchal-Davin, Claire
A1 Espié, Marc
A1 Giacchetti, Sylvie
A1 Charveriat, Patrick
A1 Plu-Bureau, Geneviève
A1 Maitrot-Mantelet, Lorraine
A1 Gompel, Anne
A1 Chapron, Charles
A1 Santulli, Pietro
A1 Asselain, Bernard
A1 Hotton, Judicaël
A1 Coutant, Charles
A1 Guerin, Julien
A1 Decanter, Christine
A1 Mailliez, Audrey
A1 Delrieu, Lidia
A1 Dumas, Elise
A1 Sablone, Laura
A1 ,
A1 Reyal, Fabien
A1 Hamy, Anne-Sophie
YR 2021
UL http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267867.abstract
AB Objective To compare the prevalence of contraception in breast cancer (BC) patients at risk of unintentional pregnancy (i.e. not currently pregnant or trying to get pregnant) and matched controls.Design The FEERIC study (Fertility, Pregnancy, Contraception after BC in France) is a prospective, multicenter case-control study. Data were collected through online questionnaires completed on the Seintinelles* research platform.Setting Not applicablePatient(s) BC patients aged 18-43 years, matched for age and parity to cancer-free volunteer controls in a 1:2 ratio.Intervention(s) NoneResults In a population of 1278 women at risk of unintentional pregnancy, the prevalence of contraception at study inclusion did not differ significantly between cases (340/431, 78.9%) and controls (666/847, 78.6%, p=0.97). However, the contraceptive methods used were significantly different, with a higher proportion of copper IUD use in BC survivors (59.5% versus 25.0% in controls p<0.001). For patients at risk of unintentional pregnancy, receiving information about chemotherapy-induced ovary damage at BC diagnosis (OR= 2.47 95%CI [1.39 - 4.37] and anti-HER2 treatment (OR=2.46, 95% CI [1.14 - 6.16]) were significantly associated with the use of a contraception in multivariate analysis.Discussion In this large French study, BC survivors had a prevalence of contraception use similar to that for matched controls, though almost one in five women at risk of unintentional pregnancy did not use contraception. Dedicated consultations at cancer care centers could further improve access to information and contraception counseling.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe FEERIC study was funded by Institut du Cancer InCA, InCA-SHS, grant No. 2016-124, and is part of the Young Breast Cancer Project, funded by Monoprix*. The funder was not involved in study design, or in the collection, analysis, and interpretation of data, the writing of this article or the decision to submit it for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data were collected via self-administered online questionnaires released through the Seintinelles* research platform. Seintinelles* is a collaborative social network created in 2012 to accelerate the recruitment of French volunteers for cancer research studies, by connecting researchers with men and women of various ages, social and medical backgrounds, with or without a history of BC, willing to participate in research studies. The scientific board of the Seintinelles approved the FEERIC project in December 2015, and the ethics board of Sud Ouest Outre Mer II approved the project on October 5, 2017. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript